Return to content in this issue

 

Allergy IgE-mediated to Pembrolizumab and Successful Desensitization

Torrado I1, Peña Mª I1,4, Tsopana A1, Mendoza I2, Beitia JM1,4, Mateo B1,4, Chara LE3, Vega A1,4

1Allergy Service, Hospital University of Guadalajara, Spain. Allergological diagnosis of the patient and acquisition of data.
2Pharmacy Service, Hospital University of Guadalajara, Spain. Preparations of the skin tests, the solution for the desensitization and indications of stability.
3Oncology Service, Hospital University of Guadalajara, Spain. Diagnosis of the patient and controls.
4ARADyAL Spanish Thematic Network and Co-operative Research Centre RD16/0006/0023, ISCIII, Madrid, Spain


J Investig Allergol Clin Immunol 2023; Vol. 33(4)
doi: 10.18176/jiaci.0858

Key words: Pembrolizumab, Allergy, Desensitization, Lung cancer, Anti-PD-1 antibody